Experiences of a Bioinformatics Company in. Dr Othmar Pfannes 4 November 2016 Basel

Similar documents
World s Leading Pharmaceutical R&D and Manufacturing Trade Show

Exhibition & Conference

Index Day reports (ADR)...59, 125

Asia s Premier Partnering Event for the Biotechnology Industry. Makoto TANIHARA ICS Convention Design, Inc.

2010/SOM3/LSIF/002. Opening Remarks. Submitted by: Japan Pharmaceutical Manufacturers Association (JPMA)

POSTER PRESENTATIONS & POSTER DISCUSSIONS

Table of contents. Executive Summary. Chapter 1 Introduction. Chapter 2 Trends in monoclonal antibody dealmaking

MARKETS & CUSTOMERS. Progressing globalization. Evolving markets

Scilab & Scilab Cloud

Helping unlock growth opportunities worldwide

Territory Account Manager (MD, NC or TX based)

Organizational Capability and Competitive. Advantage in Pharmaceutical Product Development

Regenerative Medicine in Japan

Welcome to December Hotel Okura Tokyo, Japan

Datamonitor Healthcare Pharma intelligence informa Datamonitor Healthcare Content Calendar

The Role of the European Environment Agency and EU Environmental Policies

Biotech in Japan: leveraging unexploited opportunities. Seiji Hirasaki, AnGes MG 14 March 2008 JETRO Japan Seminar at BioSquare

Technology Transfer, Academic and Industry Cooperations

Regulatory Progress of 3D Printing in Taiwan

Human ips/es Cell Technology and Its Application to Toxicology Testing

Mitsubishi Pharma Corporation reaches a basic agreement to merge with Tanabe Seiyaku Co., Ltd.

Accelrys ROTH Growth Stock Conference

U.S. NUCLEAR POWER PLANT DECOMMISSIONING

Decisions taken in COP16 and 17: The MRV landscape

Objective. To discuss how Japan sites can conduct Investigator Initiated Clinical Research/Trials (IITs) using unapproved drugs at an early stage

Guide to Valuation of Pharmaceutical Licensing Deals

JP Morgan. Global Healthcare Conference. Robert Friel, Chairman and CEO January 11, PerkinElmer

Three Actions for LCSs

Evaluate Data Kit Pharma, Biotech and Medtech, May 2018

CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS

Investigator Initiated Research and Data Usage in Japan

ARQULE AND DAIICHI-SANKYO ENTER INTO STRATEGIC R&D PARTNERSHIP TO PROGRESS NOVEL COMPOUNDS TO TARGET CANCER

An integrated model approach to improve the management of marketed products

Outreach in Japan. HESI Assembly of Members Annual Business Meeting May 12, Ayako Takei HESI Scientific Advisor in Japan

PRELIMINARY AGENDA ** Attendees must already be registered to attend cphi Japan conference**

GENE EXPRESSION REAGENTS MARKETS (SAMPLE COPY, NOT FOR RESALE)

M a x i m i z in g Value from NGS Analytics in t h e E n terprise

Astellas Reports Financial Results for the First Nine Months of FY2017

Japan's New Growth Strategy: MSD s Contribution as a Global Company

Measuring Broadband America:

Innovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing

Janssens Discovery Data Integrity program (DDI): A journey over the last 7 years Research Integrity: Position yourself for success!

Passion for Excellence. Commitment to Delivery.

Japan Pharma Outlook 2027 Report Extract

Novartis Business Services HR University Relations. Chemical and Analytical Development. Early Talent Program

Developing Strong Partnerships to Ensure Success With Global Medical Device Trials. 23-February-2017, OCT Burlingame

Investor Overview Presentation ADVANCING LIFE SCIENCE TOGETHER

MES Middle Ages Evolution Space. Florian Seitz Werum Asia Support Centre

Policies that encourage innovation in middle-income countries

Career Growth Areas in Physiology / Pharmacology

Japan: A practical approach and challenges for Europeans

BIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS

2 Day Seminar Assuring Data Integrity in the Life Science industry. Manufacturers

Collaborative Robots and Industry 4.0. A Technology Leader

Quintiles Transnational Corporation Big is Beautiful

Non Deal Roadshow - Europe

Global Competitiveness, Market Demand and the US Plastics Processing Industry

Application-Centric Transformation for the Digital Age

Company Profile. German-Taiwan Biotech Seminar 6 November 2017

Solid and stable core business and Steady development of a growth business

Experience of Medicago working with Innovation intensive Japanese companies in the life sciences sector.

Corporate Reputation of Pharma in 2017 the Patient Perspective

Pharma. Vision. The first single view of the risk and reward of the R&D landscape

The Lessons from Indonesia

Updates on Tuna farming. Status on the Bluefin Tuna Seedling Production and Farming in Japan. TUNA th May 2018, Bangkok

JAPANESE INDUSTRY S ACTIVITIES IN BRAZIL 2018 DECEMBER 3 JAPAN EXTERNAL TRADE ORGANIZATION(JETRO) SAO PAULO OFFICE

PMDA Perspectives Yoshihiro Matsuda, Ph.D.

PerkinElmer, Inc. JP Morgan Global Healthcare Conference. Robert Friel, Chairman and CEO January 14, 2015 HUMAN HEALTH ENVIRONMENTAL HEALTH

Pharma/Life Sciences Hiring and Compensation Trends

Namiki Shoji Co., Ltd.:

to acquire Investor And Analyst Call Presentation January 4, 2008

BIOTECH OUT-LICENSING OPTIMIZED COMPOUND VALUE

Strategic vision of Pharma Market

New vision for the pharmaceutical industry

Global Life Sciences BPO Market to be Worth USD 596 Billion by 2019: Transparency Market Research

Recent Developments of AEO Program in Japan

On the Radar: Liaison Technologies

Open Innovation to Improve Healthcare

Overview of the current Japanese biotech industry and investment outlook

Welcome to CMC Strategy Forum Japan 2017

Pharma. Vision. The first single view of the risk and reward of the R&D landscape

Antibody Discovery at Evotec

Real solutions for real-world problems.

The commercialization of biotechnology in Japan

Erythropoiesis-Stimulating Agents and Beyond: A Review of the Current Landscape of Renal Anemia Research

About DRG Consulting 1

L A B O R M A R K E T B R I E F I N G S S E R I E S

2 nd JAPAN- INDIA MEDICAL PRODUTS REGULATION SYMPOSIUM. 24 th APRIL 2017 QUALITY STANDARDS AND GMP SYSTEM IN INDIA

Market Report Biopharmaceuticals and Biosimilars

Build v/s Buy Laboratory Information Management System

IEEJ: August 2012 All Right Reserved Ministry of infrastructure and energy Republic of Serbia IEEJ : June 2012 JICA TRAINING AND DIALOG PROGRAMS ENERG

Strategic Overview of the Biotechnology Industry

Secure Interim Analysis Data Access. Management with ACES. Eric J. Silva, Cytel, Inc. Steven Ketchum, Ph.D., Sunesis Pharmaceuticals

COUNTERFEIT PURCHASES: DELIBERATE OR NOT?

The Geopolitics of Northeast Asia s Pipeline Development

Welcome to CMC Strategy Forum Japan 2015

Dramatic Changes in the Environment for New Drug Creation and Challenges Facing Japan s Pharmaceutical Industry

PHARMACEUTICALS EXPORT PROMOTION COUNCIL (Set up by Ministry of Commerce, Govt. of India)

List of contributors List of abbreviations. 1 The business of healthcare innovation in the Wharton School curriculum 1

PMDA Activities for Implementation of Continuous Manufacturing

Transcription:

Experiences of a Bioinformatics Company in Dr Othmar Pfannes 4 November 2016 Basel

Agenda About Genedata Genedata in Japan Q&A 2

Genedata Snapshot Roots Established in 1997 Privately owned Headquartered in Switzerland Global Reach ~ 200 employees Offices in Europe (Basel, Munich), North America (Boston, San Francisco) & Asia (Tokyo) Innovative Leader enterprise software systems for genedata related research & development Unique Domain Expertise Experienced Ph.D. level experts coupled with efficient software engineering processes Marquee Customer Base Leading pharmaceutical, biotechnology, and other life science organizations 3

Marquee Customer Base 25 of Top 25 BioPharma 5 of Top 5 Agri Biotechs Leading Industrial Biotechs San Francisco Boston Basel Munich Tokyo 2016 Genedata CONFIDENTIAL 4

Solutions from Discovery to Manufacturing Biologics Large-molecule discovery Bioprocess Large-molecule development Expressionist Analytical characterization Imagence Image-based research Profiler Patient characterization Screener Molecular identification Selector Cell line optimization Target Discovery Lead Discovery Translational Research Pre-clinical Development Clinical Development Manufacture 5

Our Business Model Analytical Workflow Systems Enterprise, modular, turn-key Domain Expertise unique mix of science, IT & business know-how Top50 Pharma, Biopharma, Industrial & Agro Biotech Creating Efficiencies automating complex R&D workflows Enabling Innovation providing scalable data analytics Selling Software Licenses & Consulting 2016 Genedata CONFIDENTIAL 6

Why Japan? Global Ranking Top 10 Japanese Pharma Companies Rev 2015 [in Mio $] 17 Takeda 13,681 19 Astellas 11,391 21 Daiichi Sankyo 8,612 27 Otsuka HD 7,742 33 Eisai 4,263 36 Chugai 4,139 38 Mitsubishi Tanabe 3,551 41 Sumitomo Dainippon 2,996 47 Shionogi 2,507 49 Kyowa Hakko Kirin 2,317 7

Genedata s success in Japan: 7 out of Top10 (plus 2) Global Ranking Top 10 Japanese Pharma Companies Rev 2015 [in Mio $] 17 Takeda (2009) 13,681 19 Astellas (2008) 11,391 21 Daiichi Sankyo (2009) 8,612 27 Otsuka HD 7,742 33 Eisai (2011) 4,263 36 Chugai (2007) 4,139 38 Mitsubishi Tanabe (2015) 3,551 41 Sumitomo Dainippon 2,996 47 Shionogi (2013) 2,507 49 Kyowa Hakko Kirin 2,317 Taisho (2014) Ono (2011) 8

Genedata Japanese History 1997-2000 Early Successes in Europe Global Expansion to US & JP 2001 Started with Japanese Distributor in JP not successful 2005 Founded Genedata KK with office in Tokyo & 2 employees 2011 Break-even 2016 Profitable Growing Business 10 FTEs Only 2 of 7 solutions currently offered in Japan 9

KK revenue 2007-2017 300000000 250000000 Exchange Rate Forecasts 200000000 150000000 100000000 50000000 0 Y 2007 Y 2008 Y 2009 Y 2010 Y 2011 Y 2012 Y 2013 Y 2014 Y 2015 Y 2016 Y 2017 10

Why are we successful in Japan? High quality of Genedata solutions Unique end-to-end enterprise product Continuous high-quality support from Basel Flexibility in price Understanding Japanese business culture & market situation Realistic growth expectations 11

Some Observations Japanese customers require high quality product very demanding wrt support committed if you deliver on promises Doing business in Japan structured & well organized predictable & transparent Japanese Personnel high scientific quality eager to learn hard working committed English language skills are big problem Managing Director with great business skills key for success 12

Where do we go from here in Japan? Continue with natural growth path Grow when Japanese market is ready Currently introducing 3 rd product to Japanese market Plan to hire ~ 1 FTE/year Scientific domain expertise, business understanding & communication skills Invest significantly in training Try closing deals at higher decision level Increased deal sizes Genedata solutions become part of infrastructure Building trust level at senior management Expansion to new markets beyond pharma Agri-Business? Industrial Biotech? Consumer Goods? 13

ご清聴有難う御座いました 14